Butterfly Network Partners with Stealth Startup Bridge Neurotech on Non-Invasive Brain-Computer Interface
BFLY has more than doubled off its 52-week low of $1.9.
Summary
Butterfly Network announced a multi-year R&D agreement with Bridge Neurotech, a startup emerging from stealth to develop a fully non-invasive brain-computer interface using ultrasound. Bridge will license Butterfly's Ultrasound-on-Chip technology through Butterfly Embedded, with payments for technology access, development milestones, and hardware purchase commitments. The deal expands Butterfly's licensing business into the high-profile BCI space, potentially opening a new revenue stream beyond its core point-of-care ultrasound market. Bridge's first human research study is now enrolling participants in Redwood City, California. This follows Butterfly's strong Q2 results and a wave of insider selling by founder Jonathan Rothberg and other executives, making this partnership a notable positive development for the company's growth narrative.
At the time of this announcement, BFLY was trading at $8.75 on NYSE in the Technology sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $1.90 to $10.21. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.